[go: up one dir, main page]

MEP16608A - Pharmaceutical compositions based on azetidine derivatives - Google Patents

Pharmaceutical compositions based on azetidine derivatives

Info

Publication number
MEP16608A
MEP16608A MEP-166/08A MEP16608A MEP16608A ME P16608 A MEP16608 A ME P16608A ME P16608 A MEP16608 A ME P16608A ME P16608 A MEP16608 A ME P16608A
Authority
ME
Montenegro
Prior art keywords
azetidine
derivatives
general formula
azetidine derivatives
action
Prior art date
Application number
MEP-166/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Sophie Cote
Valerie Bobineau
Maria-Teresa Peracchia
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP16608A publication Critical patent/MEP16608A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-166/08A 2001-12-21 2002-12-20 Pharmaceutical compositions based on azetidine derivatives MEP16608A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0116638A FR2833842B1 (fr) 2001-12-21 2001-12-21 Compositions pharmaceutiques a base de derives d'azetidine
PCT/FR2002/004514 WO2003053431A2 (fr) 2001-12-21 2002-12-20 Compositions pharmaceutiques a base de derives d'azetidine
YUP-555/04A RS55504A (sr) 2001-12-21 2002-12-20 Farmaceutski oblici na bazi derivata azetidina

Publications (1)

Publication Number Publication Date
MEP16608A true MEP16608A (en) 2010-06-10

Family

ID=8870824

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-166/08A MEP16608A (en) 2001-12-21 2002-12-20 Pharmaceutical compositions based on azetidine derivatives

Country Status (31)

Country Link
EP (1) EP1458413B1 (xx)
JP (1) JP5021887B2 (xx)
KR (1) KR20040068308A (xx)
CN (1) CN100388918C (xx)
AP (1) AP1754A (xx)
AR (1) AR037687A1 (xx)
AU (1) AU2002364866B2 (xx)
BR (1) BR0215048A (xx)
CA (1) CA2470443A1 (xx)
CO (1) CO5590911A2 (xx)
DE (1) DE60233071D1 (xx)
DK (1) DK1458413T3 (xx)
EA (1) EA006510B1 (xx)
EC (1) ECSP045162A (xx)
FR (1) FR2833842B1 (xx)
HR (1) HRP20040575A2 (xx)
HU (1) HUP0402586A3 (xx)
IL (1) IL162563A0 (xx)
MA (1) MA27086A1 (xx)
ME (1) MEP16608A (xx)
MX (1) MXPA04005558A (xx)
MY (1) MY138172A (xx)
NO (1) NO20042781L (xx)
NZ (1) NZ533225A (xx)
OA (1) OA12750A (xx)
PL (1) PL203248B1 (xx)
RS (1) RS55504A (xx)
TW (1) TWI256304B (xx)
UA (1) UA77736C2 (xx)
WO (1) WO2003053431A2 (xx)
ZA (1) ZA200404338B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
BRPI0507801A (pt) 2004-02-17 2007-07-10 Esteve Labor Dr compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
BRPI0806312A2 (pt) 2007-01-04 2011-09-06 Prosidion Ltd agonistas cgpr piperidina
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
JP2010514828A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
FR2923719B1 (fr) * 2007-11-15 2009-11-20 Sanofi Aventis Compositions pharmaceutiques a base de derives d'azetidine
FR2928149B1 (fr) 2008-02-29 2011-01-14 Sanofi Aventis Composes derives d'azetidines, leur preparation et leur application en therapeutique
FR2946650B1 (fr) * 2009-06-16 2011-08-19 Sanofi Aventis Esters derives d'azetidines, leur preparation et leur application en therapeutique.
UA153183U (uk) 2022-10-27 2023-05-31 Андрій Валерійович Максимов Стаканчик для приготування напою

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR73668B (xx) * 1978-11-21 1984-03-28 Hoffmann La Roche
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HRP980026A2 (en) * 1998-01-20 1999-10-31 Pliva Pharm & Chem Works 1-izothiazolydinone derivatives of azetidine-2-ones, processes for the preparation and use thereof
AU4989299A (en) * 1998-07-14 2000-02-07 Em Industries, Inc. Microdisperse drug delivery systems
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Also Published As

Publication number Publication date
HUP0402586A3 (en) 2011-05-30
PL372708A1 (en) 2005-07-25
ECSP045162A (es) 2004-08-27
CA2470443A1 (fr) 2003-07-03
UA77736C2 (en) 2007-01-15
HUP0402586A2 (hu) 2005-03-29
NO20042781L (no) 2004-09-20
KR20040068308A (ko) 2004-07-30
DK1458413T3 (da) 2009-11-23
NZ533225A (en) 2007-02-23
PL203248B1 (pl) 2009-09-30
FR2833842B1 (fr) 2004-02-13
DE60233071D1 (de) 2009-09-03
MY138172A (en) 2009-04-30
BR0215048A (pt) 2004-11-03
AR037687A1 (es) 2004-12-01
CO5590911A2 (es) 2005-12-30
AP1754A (en) 2007-07-18
MA27086A1 (fr) 2004-12-20
RS55504A (sr) 2007-06-04
MXPA04005558A (es) 2004-12-06
EP1458413B1 (fr) 2009-07-22
AU2002364866B2 (en) 2006-11-30
TWI256304B (en) 2006-06-11
WO2003053431A2 (fr) 2003-07-03
CN100388918C (zh) 2008-05-21
AP2004003066A0 (en) 2004-06-30
OA12750A (fr) 2006-07-03
AU2002364866A1 (en) 2003-07-09
HRP20040575A2 (en) 2004-10-31
EA006510B1 (ru) 2005-12-29
ZA200404338B (en) 2005-06-02
IL162563A0 (en) 2005-11-20
CN1602206A (zh) 2005-03-30
JP5021887B2 (ja) 2012-09-12
EP1458413A2 (fr) 2004-09-22
HK1070840A1 (zh) 2005-06-30
TW200301108A (en) 2003-07-01
FR2833842A1 (fr) 2003-06-27
WO2003053431A3 (fr) 2003-12-18
EA200400843A1 (ru) 2004-12-30
JP2005516945A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
MEP16608A (en) Pharmaceutical compositions based on azetidine derivatives
DK0991407T3 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
BR112015006537A2 (pt) dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
ECSP044974A (es) Formulación de suspensión oral estabilizada
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
NO20085087L (no) Nye heterocykliske forbindelser
NO20000466L (no) Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
NO20042459L (no) Vannbasert farmasoytiske formuleringer av vannloselige prodrug av propofol
CO5540294A2 (es) Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
EA200500671A1 (ru) Фармацевтический состав оланзапина
ATE491447T1 (de) Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen
HRPK20030766B3 (en) Combination of a taxane and cyclin-dependent kinase inhibitor
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
TH65152A (th) องค์ประกอบทางเภสัชกรรมที่อยู่บนพื้นฐานของอนุพันธ์อะซีทิดีน
SE0102933D0 (sv) Lipid carrier
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
ATE355084T1 (de) Pharmazeutische zusammensetzungen von lavendustin
RU2003125674A (ru) Жидкая фармацевтическая композиция